Podcasts about Bruton

It's the last BEHIND THE LENS for 2025! And this week, we shine a light on producer, director, writer, and actor RYAN FRANCIS and his latest film, SPEED TRAIN. I have had the pleasure of knowing Ryan for more than two decades. I reviewed his first directorial short film and multiple feature films thereafter, and interviewed him. And over the years, he has moved from being an actor in front of the camera to going behind the camera into directing and, most recently, also producing. And now he brings us a fast-paced, entertaining futuristic film that posits some interesting questions for us as individuals and a society – SPEED TRAIN. In this very candid, fun, and unfettered exclusive interview, writer/director RYAN FRANCIS discusses his career growth from acting to directing, highlighting his recent film SPEED TRAIN, as well as discussing at length some of his prior films of late in which he only acts or serves an Executive Producer versus directing; notably, "Reverence", "The Jurassic Games: Extinction", "Trail of Vengeance", "The Flood", and "3 Days in Malay". He also discusses two upcoming films he's excited about, "Bruton" and "Bring the Law." As we specifically dig into the making of SPEED TRAIN, Ryan shares the challenges of directing a futuristic sci-fi film in 12 days with a small budget, praising his team, including DP Nico De La Fere and editor Austin Nordell, as well as producer Daemon Hillin and his Thailand team. A large portion of our conversation also discusses the film's themes of AI and human reliance on technology. An interesting aspect of our discussion revolved around the challenges of the film industry, the importance of maintaining a passion for making movies, and the need to bring audiences back to the theater experience. As you'll hear, Ryan speaks with a mix of candor, humor, and hard-earned perspective about a career that has quietly but decisively evolved. Once primarily known as an actor, Ryan has increasingly stepped behind the camera, carving out a space as a filmmaker unafraid of ambition—or of admitting when that ambition nearly outruns the clock. http://eliasentertainmentnetwork.com

JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I'm Jonathan Friedberg, editor of Journal of Clinical Oncology, and welcome to JCO After Hours, where we are covering two manuscripts that were presented at the American Society of Hematology meeting 2025 in Orlando, Florida. I am delighted to be joined by colleagues on this call to discuss these pivotal manuscripts which cover the topic of pirtobrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. I will first just introduce our guests, Dr. Woyach. Dr. Jennifer Woyach: Hi, my name is Jennifer Woyach. I am from the Ohio State University. Dr. Wojciech Jurczak: Hello, I am Wojciech Jurczak, working at the National Research Institute of Oncology in Krakow, Poland. Dr. Matthew Davids: Hi, I am Matthew Davids from Dana-Farber Cancer Institute in Boston. Dr. Jonathan Friedberg: We are going to start by just learning a little bit about these two trials that were both large, randomized phase 3 studies that I think answered some definitive questions. We will start with your study, Jennifer. If you could just describe the design of your study and the patient population. Dr. Jennifer Woyach: Absolutely. So this is the BRUIN CLL-314 study, and this is a phase 3 randomized trial of pirtobrutinib versus ibrutinib in patients with CLL or SLL who had not previously been treated with a covalent BTK inhibitor. The patients were both treatment-naive and relapsed/refractory, about one-third of the patients treatment-naive, the rest relapsed/refractory, and they were stratified based upon 17p deletion and the number of prior lines of therapy. The primary objective was looking at non-inferiority of overall response rate over the entire treated population as well as the relapsed/refractory patient population. Key secondary objectives included progression-free survival in the intention-to-treat and the smaller relapsed/refractory and treatment-naive populations. Dr. Jonathan Friedberg: And just comment a little bit on the risk of the patients. Dr. Jennifer Woyach: This study was fairly typical of this cohort of patients. Within the relapsed/refractory patient population, there was a median of one prior line of therapy in each of the groups, up to nine prior lines of therapy in the patients included on the study. For the overall cohort, about two-thirds of the patients were IGHV unmutated, about 15% had 17p deletion, 30% had TP53 mutations, and about 35% to 40% had a complex karyotype, which is three or more abnormalities. Dr. Jonathan Friedberg: And what were your findings? Dr. Jennifer Woyach: Regarding the primary outcome, which is the focus of the publication, we did find that pirtobrutinib was indeed non-inferior and actually superior to ibrutinib for overall response rate throughout the entire patient population and in both the relapsed/refractory and treatment-naive cohorts. PFS is a little bit immature at this time but is trending towards also being significantly better in pirtobrutinib-treated patients compared with ibrutinib-treated patients. Probably most significantly, we found this to be the case in the treatment-naive cohort where there was a striking trend to an advantage of pirtobrutinib versus ibrutinib. Dr. Jonathan Friedberg: And the follow-up that you have on that progression-free survival? Dr. Jennifer Woyach: So we have about 18 months follow-up on progression-free survival. Dr. Jonathan Friedberg: The second study, Wojciech, can you just go through the design and patient population that you treated? Dr. Wojciech Jurczak: Thank you, Dr. Friedberg, for this question. So the BRUIN CLL-313 study was, in fact, the first phase 3 study with pirtobrutinib in exclusively untreated CLL patients. It was a randomized study where we challenged pirtobrutinib versus bendamustine-rituximab. At the time we designed the protocol, bendamustine-rituximab was an option as a standard of care, and Bruton tyrosine kinase monotherapy was used far more commonly than nowadays. The primary target of the study was progression-free survival. We took all untreated patients except for those with 17p deletions. Therefore, it is a good representation for intermediate risk. We had about 60% of the population, 56 to be precise, which was unmutated, evenly distributed into two treatment arms. 17p deleted cases were excluded, but we had about 7% and 8% of TP53 mutated patients as well as about 11% and 7%, respectively, in the pirtobrutinib and bendamustine-rituximab arm of patients with complex karyotype. The progression-free survival was in favor of pirtobrutinib and was assessed by an independent review committee. What is important is that the progression-free survival of the bendamustine-rituximab arm was actually similar to the other studies addressing the same questions, like the comparison with ibrutinib in the ALLIANCE study or zanubrutinib in the SEQUOIA study. What was different was the hazard ratio. In our study, it was 0.20. It was one of the longest effect sizes noted in the frontline BTK study. It represented an 80% reduction in progression-free survival or death. If we compare it to ibrutinib or zanubrutinib, it was 0.39 and 0.42 respectively. Presumably, this great effect contributed towards a trend of overall survival difference. Although survival data are not mature enough, there is a clear trend represented by three patients we lost in the pirtobrutinib arm versus 10 patients lost in the bendamustine-rituximab arm. This trend in overall survival is becoming statistically significant despite the fact that there was a possibility of crossover, and effectively 52.9 patients, which means 18 out of 34 patients relapsing in the bendamustine-rituximab arm, were treated by pirtobrutinib. Dr. Jonathan Friedberg: I am going to turn it over to Matt. The question is: why study pirtobrutinib in this patient population? And then with these two studies, how do you find the patients that were treated, are they representative of people who you see? And do you see this maybe being approved and more widely available? Dr. Matthew Davids: I think in terms of the first question, why study this in a frontline population, we have seen very impressive data with pirtobrutinib in a very difficult-to-treat population of CLL patients. This was from the original BRUIN phase 1/2 study where most of the patients had at least two or three lines of therapy, often both a covalent BTK inhibitor and the BCL2 inhibitor venetoclax, and yet they were still responding to pirtobrutinib. The drug was also very well tolerated in that early phase experience. And actually, we have seen phase 3 data from the BRUIN 321 study comparing pirtobrutinib to bendamustine and rituximab in a relapse population as well. So I think that really motivated these studies to look at pirtobrutinib as a first therapy. You know, often in other cancers of course, we want to use our best therapy first, and I think these studies are an initial step at looking at that. In terms of the second question around the patient population, these are pretty representative patient populations, I would say, for most frontline CLL studies. We see patients who are a bit younger and fitter than sort of the general population of CLL patients who are treated in clinical practice, and I think that is true here as well. Median age in the sort of mid-60s here is a bit younger than the typical patients we are treating in practice. But that is not different from other CLL frontline studies that we have seen recently, so I think it makes it a little bit easier as we kind of think across studies to feel comfortable that these are relatively similar populations. Dr. Jonathan Friedberg: How do you see this either getting regulatory approval or potentially being used compared to current standard of care options? Dr. Matthew Davids: So my understanding is that both of these trials were designed with registrational intent in the frontline setting, and they are both positive studies. That is certainly very encouraging in terms of the potential for an approval here. We have seen in terms of the FDA recently some concerns around the proportion of patients who are coming from North America, and my understanding is that is relatively low on these two studies. But nonetheless, the datasets are very impressive, and so I think it is certainly supportive of regulatory approval for frontline pirtobrutinib. Dr. Jonathan Friedberg: I will ask Jennifer a question. The control arm in your study was ibrutinib, and I think many in the audience may recognize that newer, second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more frequently used now if monotherapy is decided. How do you respond to that, and how would you put your results in your pirtobrutinib arm in context with what has been observed with those agents? Dr. Jennifer Woyach: Yeah, that is a great question. Even though in the United States we are predominantly using acalabrutinib or zanubrutinib when choosing a monotherapy BTK inhibitor, this is actually not the case throughout the entire world where ibrutinib is still used very frequently. The head-to-head studies of both acalabrutinib and zanubrutinib compared to ibrutinib have shown us pretty well what the safety profile and efficacy profile of the second-generation BTK inhibitors is. So even though we do not have a head-to-head study of acalabrutinib or zanubrutinib versus pirtobrutinib, I think, given the entirety of data that we have with all of the covalent BTK inhibitors, I think we can safely look at the pirtobrutinib arm here, how the ibrutinib arm compares or performs in context with those other clinical trials. And though we really can not say anything about pirtobrutinib versus acalabrutinib or zanubrutinib, I think we can still get a good idea of what might be the clinical scenarios in which you might want to choose pirtobrutinib. Dr. Jonathan Friedberg: And Wojciech, do you agree with that? Obviously, I think you have acknowledged that chemoimmunotherapy is rarely used anymore as part of upfront treatment for CLL. So, I guess a similar question. If you were to put the pirtobrutinib result in your study in context with, I guess, more contemporary type controls, would you agree that it is competitive? Dr. Wojciech Jurczak: Well, I think that that was the last study ever where bendamustine-rituximab was used as a comparator arm. So we should notice that smashing difference. Because if we look at the progression-free survival at two years, we have 93.4% in pirtobrutinib arm versus 70.7% in bendamustine-rituximab arm. Bendamustine-rituximab arm did the same as in the other trials, like ALLIANCE or SEQUOIA. Pirtobrutinib did exceptionally well, as pirto is not just the very best BTK inhibitor overcoming the resistance, but perhaps even more important for the first line, it is very well tolerated and is a very selective drug. Now, if we look at treatment-related adverse events, the discontinuation rate, they were hardly ever seen. If we compared the adverse events in exposure-adjusted incidence, literally all adverse events were two or three times higher in bendamustine-rituximab arm except for the bleeding tendency, which however was predominantly in CTCAE grade 1 and 2 with just 0.7% of grade 3 hemorrhage. Therefore, I think that we should actually put the best and the safest drugs upfront if we may, and pirtobrutinib is, or should be, the first choice if we choose monotherapy. Now, I understand that we are not presenting you the data of pirtobrutinib in combination with anti-CD20 or with BCL2 inhibitors, but that is to come. Dr. Jonathan Friedberg: Matt, how would you envision, were regulatory approval granted and this were an option, using this in the upfront patient population? Is there anybody who you would preferentially use this or start on this treatment? Or would this be something that you would tend to reserve for second line? Dr. Matthew Davids: So I would say that in general for most of my patients who would want to start with a continuous BTK inhibitor, I would still use a covalent BTK inhibitor, and I say that for a couple of reasons despite the very promising data from these studies. The first is that the follow-up for both of these phase 3 trials is still quite short, in the range of a median 18 to 24 months. And we know that CLL is a marathon, not a sprint, and these patients are going to probably be living for a very long time. And we do have much longer follow-up from the covalent BTK inhibitors, median of 10-year follow-up with ibrutinib and five to six years with zanubrutinib and acalabrutinib respectively. And you know, I do not think that the pirtobrutinib is going to fall off a cliff after two years, but on the other hand, I think there is a lot of value to long-term data in this disease, and that is why I think for most of my patients I would stick with covalent BTK inhibitors. But the other important factor that we need to consider is patients who are younger and may have many different CLL treatments over the years. We have to be very careful, I think, about how we sequence these drugs. We know right now that we can start with covalent BTK inhibitors and then subsequently patients will respond well to the non-covalent inhibitor pirtobrutinib in later lines of therapy. But right now we do not have prospective data the other way around. So how will the patients on these studies who progress on pirtobrutinib respond to covalent BTK inhibitors? We do not know yet. There have not been a lot of progression events, which is great, but we would like to see some data in that respect to feel more comfortable with that sequence. Now, I do think that particularly for older patients and those who have significant cardiovascular comorbidities, if they wanted to go on a continuous BTK inhibitor, I do think these data really strongly support using pirtobrutinib as the BTK inhibitor of choice in that population. In particular, the cardiovascular risks with pirtobrutinib seem to be quite low. I was very struck in the comparison with BR that the rate of AFib was equivalent between the two arms of the study. And that is really the first time we have seen that with any of these BTK inhibitors, no elevated risk of AFib in a randomized study. I think that is the population where it will get the most traction first, is the upfront, sort of older patient with significant cardiovascular comorbidities. And as the data from these studies mature, I think that we will start to see more widespread use of pirtobrutinib in the frontline setting. Dr. Jonathan Friedberg: Jennifer, I am just curious if you have any personal experience or heard anecdotally about after progression on pirtobrutinib the use of other BTK inhibitors and whether there is a growing experience there. Dr. Jennifer Woyach: I do not think that there is much clinical experience, you know, as Matt alluded to, it certainly has not been tested yet. There has been some data in relapsed CLL suggesting that in people who have resistance mutations to covalent BTK inhibitors after treatment with pirtobrutinib, sometimes those mutations go away. I think most of us are concerned that they are probably not actually gone but maybe in compartments that we just have not sampled, suggesting that sort of approach where you might sequence a covalent inhibitor after a non-covalent in somebody who had already been resistant probably would not work that well. But, you know, in this setting where people had never been exposed to a covalent BTK inhibitor before, we really have no idea what the resistance patterns are going to be like. We assume they will be the same as what we have seen in relapsed CLL, but I think we just need some longer follow-up to know for sure. Dr. Wojciech Jurczak: If I may confront Dr. Davids about the use of covalent BTK inhibitors upfront, well, I think that we should abandon the idea of using the first and the second and the third generation, at least if we don't have medical lines. If we endlessly block the same pathway, it is not going to be effective. So if pirtobrutinib gets approval in first, second line, we do not necessarily have to use it in the first line. I am not here in a position to defend that we should treat patients with pirtobrutinib upfront and not BCL2 time-limited regimen. However, the way I look at CLL patients when choosing therapy is not just how should I treat them now, but what would be the best regimen in 5, 10 years if I have to re-treat them. And in some instances, the idea may be that in this setting we would like to have a BTK inhibitor upfront to have a BCL2 inhibitor later to make it time-limited. Although I understand and I agree with Matthew that if we have an elderly, fragile population, then the charm of having a drug taken once a day in a tablet with literally few cardiovascular adverse events might be an option. Dr. Jonathan Friedberg: And I will give Matt the last word whether he wants to respond to that, and also just as a forward-looking issue, I know both investigators have implied that there will be future studies looking at combinations with pirtobrutinib, and if you have any sense as to what you would be looking for there. Dr. Matthew Davids: The field really is heading toward time-limited therapy for most patients, I would say. There is a bit of a discrepancy right now in the field between sort of what we are doing in academic practice and what is done sort of more widely in community practice. And so right now we are going to see evolving datasets comparing these approaches. We are already seeing data now from the CLL17 study with ibrutinib comparing continuous to time-limited venetoclax-based therapy, and we are seeing similar efficacy benefits from these time-limited therapies without the need for continuous treatment. And so that is where I think some of the future studies with pirtobrutinib combining it with venetoclax and other partners are so important. Fortunately, several of these studies are already ongoing, including a phase 3 trial called CLL18, which is looking at pirtobrutinib with venetoclax, comparing that to venetoclax and obinutuzumab. So I am optimistic that we are going to be developing these very robust datasets where we can actually use pirtobrutinib in the frontline setting as a time-limited therapy as a component of a multi-drug regimen. So far, those early data are very promising. Dr. Wojciech Jurczak: Perhaps last but not least, in a single center we have treated over 300 patients with pirtobrutinib. So eventually some of them relapsed. And I must say that our experience on BCL2 inhibitors, not just venetoclax but including sonrotoclax, are appealingly good. Therefore, by using pirtobrutinib even earlier, we do not block the efficacy of other compounds. Dr. Jonathan Friedberg: All right. Well, I want to thank all of our speakers. I also want to congratulate our two guests who presented these very influential papers at the ASH Annual Meeting, and chose to publish them in JCO, so we thank you for that, and Dr. Davids for your commentary - really appreciated. That is this episode of JCO After Hours. Thank you for your attention. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Disclosures Dr. Wojciech Jurczak Consulting or Advisory Role: BeiGene, Lilly, Abbvie/Genentech, Takeda, Roche, AstraZeneca Research Funding: Roche, Takeda, Janssen-Cilag, BeiGene, AstraZeneca, Lilly, Abbvie/Genentech Dr. Jennifer Woyach Consulting or Advisory Role: Pharmacyclics, Janssen, AstraZeneca, Beigene, Loxo, Newave Pharmaceutical, Genentech, Abbvie, Merck Research Funding: Company name: Janssen, Schrodinger, beone, Abbvie, Merck, Loxo/Lilly Dr. Matthew Davids Honoraria: Curio Science, Aptitude Health, Bio Ascend, PlatformQ Health, Plexus Consulting or Advisory Role: Genentech, Janssen, Abbvie, AstraZeneca, Adaptive Biotechnologies, Ascentage Pharma, BeiGene, Lilly, Bristol-Myers Squibb, Genmab, Merck, MEI Pharma, Nuvalent, Inc., Galapagos NV, Schroedinger Research Funding: Ascentage Pharma, Novartis, MEI Pharma, AstraZeneca  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, the landscape of the pharmaceutical and biotech industries is marked by groundbreaking scientific advancements, regulatory shifts, and strategic collaborations that promise to reshape patient care and drug development significantly.A controversy has emerged in the wake of proposed changes to U.S. vaccine regulations by Dr. Vinay Prasad, a senior FDA official. This proposal has sparked considerable opposition from 12 former FDA commissioners who argue that these regulatory overhauls could potentially undermine public trust in vaccines. Former leaders from both the CDC and FDA have expressed concerns over these proposed vaccine policy changes during an ACIP meeting, discussions that could influence future public health strategies and vaccine trust. At a time when vaccine confidence is crucial, maintaining the integrity of regulatory processes is vital to public health efforts.Leadership changes are also afoot within the FDA, as Dr. Tracy Beth Hoeg steps into the role of acting director for the Center for Drug Evaluation and Research. Her appointment signals a shift towards leaders with direct experience in public health crises. This comes amidst further internal restructuring at the FDA, including the transfer of Theresa Michele, long-standing director of the Office of Nonprescription Drugs, indicating dynamic changes within the agency.In the realm of oncology, Eli Lilly's progress with its Bruton's tyrosine kinase inhibitor, Jaypirca, is noteworthy. The drug's expanded label now includes earlier treatment stages for chronic lymphocytic leukemia and small lymphocytic lymphoma. This expansion underscores the therapeutic potential of non-covalent BTK inhibitors and may significantly improve patient outcomes by offering earlier intervention options.Geopolitical challenges are impacting the industry as WuXi AppTec, a major China-based biopharmaceutical contractor, faces scrutiny from the Pentagon amid concerns about its potential ties with the Chinese military. This development highlights the complex interplay between global security concerns and international biotech collaborations. The intersection of global security concerns continues to impact biopharmaceutical supply chains as WuXi AppTec faces increased scrutiny from U.S. authorities.On the manufacturing front, Quvara Medical's emergence as a new contract development and manufacturing organization following Buckland Group's acquisition of a Becton Dickinson facility in the UK reflects industry trends toward consolidating manufacturing capabilities to meet growing biopharmaceutical demand efficiently.AstraZeneca is enhancing its pipeline through a renewed partnership with Neurimmune for an amyloidosis asset. This collaboration, potentially worth up to $780 million, highlights AstraZeneca's strategic focus on rare diseases and underscores their commitment to expanding their therapeutic portfolio through successful alliances.Regulatory updates from the FDA propose reductions in user fees for early-stage clinical trials conducted domestically while considering additional fees for overseas developments. This initiative aims to incentivize research activities within the U.S., potentially accelerating drug discovery timelines and fostering domestic innovation.In surgical technology advancements, Medtronic's Hugo surgical robot has secured FDA clearance for procedures involving prostate, kidney, and bladder removal. This marks a significant advancement in robotic-assisted surgeries and could enhance patient outcomes across approximately 230,000 surgeries annually in the U.S.As we explore more about financial maneuvers within this sector, Royalty Pharma's $275 million financing deal for Denali Therapeutics' Hunter syndrome drug reflects confidence in Denali's pipeline pendinSupport the show

In this special Derms and Conditions episode recorded live at Fall Clinical 2025, host James Q. Del Rosso, DO, is joined by April Armstrong, MD, MPH, and David Cohen, MD, to share highlights and clinical takeaways from this year's meeting. Dr Armstrong kicks off with updates in hidradenitis suppurativa (HS), noting the field's rapid progress with 3 FDA-approved therapies (adalimumab, secukinumab, and bimekizumab), emerging 3-year data for bimekizumab, and exciting new agents such as oral povorcitinib and topical ruxolitinib. She shares learnings on the importance of proactive flare management plans and setting realistic patient expectations, particularly regarding scarring and lymphedema. Dr Cohen and Dr Del Rosso echo the importance of reengaging patients with longstanding HS and highlight the promise of JAK inhibition in this complex disease. The discussion shifts to chronic spontaneous urticaria (CSU), where Dr Cohen spotlights remibrutinib, a twice-daily oral Bruton kinase inhibitor delivering rapid results sometimes within 1 to 2 weeks and potentially enabling dermatologists to manage CSU more directly. Dr Armstrong adds that dupilumab now offers another trusted option for CSU, with a head-to-head trial versus remibrutinib on the horizon. For chronic hand eczema (CHE), they discuss the paradigm-shifting approval of delgocitinib cream, a topical pan-JAK inhibitor effective across CHE subtypes and free of boxed warnings. They note strong data for pain and itch reduction and its potential to mitigate chronic steroid reliance. The episode closes with emerging oral psoriasis therapies, including 5-year deucravacitinib safety data and radiographic progression inhibition shown with guselkumab. Looking ahead, they predict major advances by 2026 in TYK2 inhibitors, OX40-targeted therapies, and personalized molecular profiling for atopic dermatitis. Tune in to the full episode for expert perspectives straight from the Fall Clinical stage!

The Go To Food Podcast returns with a legend. Margot Henderson OBE joins us for a gloriously frank, funny, and deeply human conversation about the craft of hospitality. From the early days at The Eagle and The French House to the white heat of opening St. John with Fergus Henderson, Margot traces the rise of modern British cooking, the joy of whole-animal kitchens, and the art of building atmosphere without gimmicks. Expect big stories, bigger flavours, and the kind of kitchen wisdom only a lifetime in service can teach.We record at The Three Horseshoes in Batcombe, Somerset, where the tomatoes burst like fireworks and the faggots arrive wrapped in caul and pride. Margot lifts the lid on a life spent nurturing chefs who fly the nest, the realities of PR, and why a great waiter can save a meal. She celebrates the producers around Bruton, tips her hat to Wescombe's cheddar cave, and recalls the art world and Anthony Bourdain putting rocket fuel under St. John. This is a rolling feast of memories, mishaps, and moments that changed the way Britain eats.There are love stories too. Sweetings proposals, bar counters, the rhythm of service, and the calm conviction that simple food, cooked honestly, can move a room. -------Sponsor: This episode is brought to you by Blinq—POS made simple: £69/month, unlimited devices, 24/7 UK support, no contracts or hidden fees. Use code GOTOBLINQ for a free month. Got a true kitchen nightmare? Send it in—Ben's favourite wins a year of Blinq. Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton's tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor (BCL-2i) treatment selection for patients with chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

See omnystudio.com/listener for privacy information.

NBL NOW | Everything NBLCal Bruton & Joel Peterson* Perth get the 'W' against Tasmania* Why aren’t we talking about Casey Prather more? * How you seeing Brisbane at the moment? * Jack McVeigh likely return, gives Cairns some hope? * Kings and Goorj under pressure* Big round of hoops aheadSee omnystudio.com/listener for privacy information.

For decades, allergists have focused on blocking what happens outside the mast cell: histamine, IgE, and interleukins. But now, there's a new way to stop allergic inflammation before it even starts: by targeting what happens inside the cell with BTK Inhibitors. Dr. Payel Gupta and Kortney are joined by Dr. Matthew Giannetti to unpack what BTK actually does and why inhibiting it represents an exciting breakthrough in allergy and immunology. Together, they explore how BTK inhibitors work, why this inside-the-cell approach is different from anything before, and what it could mean for people living with chronic spontaneous urticaria (CSU). What the episode covers about BTK inhibitors: BTK explained: Bruton's tyrosine kinase is a pivotal “last step” before mast-cell degranulation. How BTK inhibitors work: Blocking BTK can stop histamine release downstream of many outside triggers. The science: Why BTK binding is irreversible for each molecule and how the body “re-makes” BTK over time. Safety in brief: A look at petechiae (small pinpoint spots), what to monitor, and how shared decision-making guides treatment choices. The future of BTK inhibitors: Exploring their potential role in other allergic conditions.    ____ Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

DeAnte Bruton is a former college athlete currently working in IT. He is a BFM listener and still early on his Bitcoin journey and research. I helped to answer his big Bitcoin questions!› https://x.com/Deanteb_3PARTNERS

Jim and Evelyn Bruton, courtesy of Elanie Bruton. This is an edited version of a conversation with a  lighthouse keeper's daughter in British Columbia, Canada, first heard in episode 104 of Light Hearted. Jim Bruton was born in Wales in 1926, but his family relocated to British Columbia in Canada when he was just one year old. He started working in the logging industry as a boy. In a light keeping career spanning several decades, he served at light stations around Vancouver Island: Lennard Island, Discovery Island, and Chrome Island. Sheringham Point Lighthouse, BC. Photo by Jeremy D'Entremont. iThe Brutons eventually had four children, three girls and a boy. The family moved to Sheringham Point, a mainland lightstation in Shirley on the southwest coast of Vancouver Island, in 1968. They lived there for nearly two decades, until 1986, when Jim Bruton retired. Our guest today, Elanie Bruton, lived at the light stations with her family until she was 18. She remains an active volunteer of the Sheringham Point Lighthouse Preservation Society, which now owns the lighthouse and surrounding land.

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Julie Vose, University of Nebraska Medical Center, Omaha, US, discussing unmet needs in the treatment of MCL. Vose provides an overview of the current treatment landscape for patients with MCL, including Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies. Vose also discusses mechanisms of resistance to BTKi and the impact on patient outcomes. This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

We're discussing Relationships and Community: the Fabric of Rural Health! Faisel and Dan are joined by Dr. Sonya Bruton: CEO and President of CCI Health Services, Clinical Psychologist, and Author.Our conversation revolves around the inherent link between physical and behavioral health, the necessity of physicians staying engaged with their passion for care, and the hesitancy of patients around AI in healthcare.

In this Made in America podcast episode, Nelson Bruton, President of Manufacturing Chats, shares insights on how manufacturers can boost their sales and business growth through practical, effective communication tools like live chat. The discussion covers the evolution of Manufacturing Chats from a full-service digital marketing agency to a specialized provider of live chat solutions tailored for industrial manufacturers. Nelson emphasizes the importance of real-time customer engagement, drawing parallels between live chat and trade show interactions. He also explores the potential of AI in chat services while highlighting the continued need for human interaction in complex sales environments. This episode is a valuable resource for manufacturers looking to enhance their sales strategies and improve customer engagement.  Youtube: https://youtu.be/SIXhUjWBpA4 Podcast Website: https://madeinamerica.compassmsp.com/nelson-bruton-manufacturing-chats Nelson Bruton's LinkedIn Manufacturing Chats Website  Manufacturing Chats LinkedIn Ari Santiago's LinkedIn CompassMSP Website CompassMSP LinkedIn Made in America Podcast Facebook Made in America Podcast LinkedIn Made in America Podcast YouTube Podcast produced by Miceli Productions.  

Featuring an interview with Dr Lindsey Roeker, including the following topics: Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00) Safety of BTK inhibitors in older and frail patients with CLL (3:41) Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20) Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32) Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31) Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16) Sequencing, tolerability and future development involving pirtobrutinib (25:57) Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28) Clinical considerations in the management of Richter's transformation (38:14) Survival outcomes and quality of life for patients with CLL (41:02) Ongoing and future efforts to improve CLL treatment outcomes (45:01) CME information and select publications  

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics: Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00) Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax  (7:03) Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35) Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28) Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease  (15:52) Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12) Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor  (19:38) Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment  (22:15) Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13) Available data with epcoritamab monotherapy for R/R CLL  (26:58) The emerging pharmacologic class of BTK degraders  (29:04) CME information and select publications

A host of exhibitions and events this month and next celebrate the 100th anniversary of the birth of the Swiss artist Jean Tinguely, one of the godfathers of kinetic and auto-destructive art. Ben Luke speaks to Roland Wetzel, the director of the Tinguely Museum in Basel about the artist's life and work, and the events marking the centenary. In Rotterdam in the Netherlands, Fenix, a museum about migration, has just opened, featuring a dramatic stainless steel tornado form on its roof. We discuss the museum with its director, Anne Kremers. And this episode's Work of the Week is by an immigrant artist, Ben Shahn, who was born in modern-day Lithuania but travelled as a child to the US, where he became a leading painter associated with Social Realism. Among his greatest achievements was the mural The Meaning of Social Security, painted between 1940 and 1942 in Washington D.C. to reflect the benefits of the then-recent Social Security Act. Shahn is the subject of a major show that opened this week at the Jewish Museum in New York. We speak to Laura Katzman, the co-curator of the exhibition with the Jewish Museum's Stephen Brown, about Harvesting Wheat (1941), Shahn's study for one of the figures in the mural.The Tinguely Museum in Basel, Switzerland, has a permanent display of his work; Scream Machines–Art Ghost Train, by Rebecca Moss and Augustin Rebetez, Tinguely Museum, until 30 August; Mechanics and Humanity: Eva Aeppli and Jean Tinguely, Lehmbruck Museum, Duisburg, Germany, until 24 August; Niki de Saint Phalle & Jean Tinguely: Myths & Machines, Hauser & Wirth Somerset, Bruton, UK, until 1 February 2026; Niki de Saint Phalle, Jean Tinguely, Pontus Hultén, Grand Palais, Paris, 20 June-4 January 2026.The Fenix museum is open now.Ben Shahn: On Nonconformity, Jewish Museum, New York, 23 May-12 October. The book accompanying it published on 3 June by Princeton University Press, priced $45.00/£38.00.The Meaning of Social Security murals:https://art.gsa.gov/artworks/637/the-meaning-of-social-security?ctx=3bc918796c456cc8fb8e3d3f033918d4249d0ce6&idx=6https://livingnewdeal.org/sites/wilbur-j-cohen-building-shahn-frescoes-washington-dc/#lg=1&slide=1 Hosted on Acast. See acast.com/privacy for more information.

Over the past few years, the MS research community has been following developments in a new class of therapies called Bruton's tyrosine kinase inhibitors (BTKis). At ECTRIMS 2024, the results of two tolebrutinib trials were presented as late-breaking abstracts by Dr. Robert Fox, Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic in the US, and Dr. Jiwon Oh, Neurologist at St. Michael's Hospital at the University of Toronto. The full results were recently published in The New England Journal of Medicine. In this episode, host Brett Drummond of MStranslate spoke with Drs. Oh and Fox about the outcomes and what they mean for people with MS.

Las Vegas, Nevada is one of the most sought after tourist destinations in the world. For Mexico-born Willebaldo Dorantes Antonio, Las Vegas was booming with job opportunity and the chance to send money to his family back home. But in early May of 2007 an explosion would shock the city and leave Willebaldo's family to go on without him. Instagram: @CousinsonCrimePodcast Email: CousinsonCrime@gmail.com Theme Music by AleXZavesa Join our Patreon! https://www.patreon.com/CousinsOnCrime Check out our merch store! https://cousinsoncrime-shop.fourthwall.com/? Sources: https://www.rgj.com/story/news/crime/2022/09/29/las-vegas-police-arrest-fugitive-luxor-bomber-porfirio-duarte-herrera-after-prison-escape/10460956002/ https://www.nycourts.gov/JUDGES/evidence/4-RELEVANCE/4.20_Bruton.pdf https://www.rgj.com/story/news/2022/09/29/police-body-cam-video-luxor-bomber-porfirio-duarte-herrera-arrest/8129696001/ https://www.reviewjournal.com/news/2-avoid-death-penalty-get-life-in-prison-for-luxor-bombing/ https://case-law.vlex.com/vid/duarte-herrera-v-hutchings-934086256 https://apnews.com/article/crime-las-vegas-bombings-terrorist-attacks-de844f6f391f6472e23654573ffa921c https://apnews.com/article/las-vegas-immigration-bombings-96a60c9079984304b4bad2624d962c61

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

In this, the penultimate episode of Series 9, I talk to UKCP accredited psychotherapist Lisa Bruton who is also a guest tutor at the University of Oxford. We talk about the Parentified Child. Which is? A child who has been given too much responsibility - either physical or emotional - too young. The impact of this is interesting. Do you often find yourself being the most responsible person in the room? Do people look to you for advice (ahem) and guidance? It may be because you are used to performing this role, from way too young. Parentified children can grow up to be exhausted adults. Who looks after them? And why the phrase "my child is my best friend" gives Bruton and I pause.In this episode we look at what exactly being a parentified child looks and feels like, from both the child and adult's POV. What you can do if you recognise yourself as one and how to avoid doing that to your own children. More about Lisa here: https://www.lisabruton.comIf you'd like to support us you can leave a one off donation here: https://supporter.acast.com/conversations-with-annalisa-barbieriIf you'd like to listen to this episode, past or future ones, ad free then consider becoming a Substacker: https://pocketannalisa.substack.com/. From £5 a month or £50 a year you'll get access to all new podcasts as soon as they are available and before general release and ad-free. Plus subscriber exclusive newsletters.You can also support us by sharing this podcast far and wide, it's available wherever you listen to your podcasts. And leaving a review if you can. Thank you so much.Produced by Hester Cant. Art work by Lo Cole. Music by Toby Dunham.Support this show http://supporter.acast.com/conversations-with-annalisa-barbieri. Hosted on Acast. See acast.com/privacy for more information.

Bryan Bruton shares his insane life story! Bryan's Links https://www.youtube.com/@UC_S8-o7r0W979pS8j_7snPw https://www.instagram.com/bryanbruton_/https://www.facebook.com/bryan.bruton.2025/Go to https://ground.news/Inside for abetter way to stay informed. Subscribe for 40% off unlimited access to world-wide coverage through my link.Do you want to be a guest? Fill out the form https://forms.gle/5H7FnhvMHKtUnq7k7Send me an email here: insidetruecrime@gmail.comDo you extra clips and behind the scenes content?Subscribe to my Patreon: https://patreon.com/InsideTrueCrime

On this episode of The Claw's Corner Rich "The Claw" Cyr has a great conversation with the Raizine Bruton of Best Video! They chat all things film and video and so much more! Visit Best Video! 1842 Whitney Avenue, Hamden, CT 06517 Find Best Video online: https://www.bestvideo.com/  / bestvideohamden   https://bestvideo.creator-spring.com/ Do not miss Rich's book, "Confessions of a Frenetic Mind" available now - https://www.amazon.com/Confessions-Fr... Copyright 2025 The Claw's Corner - Produced by Rich Cyr  / richtheclawcyr   Edited by Elmwood Productions - http://elmwoodproductions.com/index.html and subscribe to Elmwood Productions on YouTube:    / elmwoodproductions   Show some love for Elmwood! It's your support that keeps content like this coming! Join our Patreon now!  / elmwoodproductions  

Partners in life and work, Jules and Steve Horell bought an old cow barn in Somerset, built a fire kitchen and started running dining experiences which they launched under the name Horrell & Horrell in 2023. I met Jules and Steve when I first moved to Bruton when he was the head chef and she was front of house at the Roth Bar & grill - the restaurant at Hauser & Wirth. Having worked in the hospitality industry for 20 years they've seen food trends come and go, climate's change and people move in & out of the area. When they decided to set they're own thing up, they were able to come up with a concept that was true to them; Friendly, delicious and homely. And they make it all happen so effortlessly! I sat down with Jules in their home kitchen and chat about how it all started. Welcome to the podcast Jules Horrell. Hosted on Acast. See acast.com/privacy for more information.

For The Other Side NDE Videos Visit ▶️ youtube.com/@TheOtherSideNDEYT Today, a skilled pilot shares the gripping story of his near-death experience following a plane crash that should have claimed his life. In the moments beyond consciousness, he entered a space where time and reality blurred, encountering a presence that offered him a choice—to move on or return. Faced with this life-altering decision, he gained powerful insights into the interconnectedness of fate, free will, and the unseen guidance shaping our lives. ⭐ Check Out More Of Jim's Near Death Experience NDE On His Website

Summary of Criminal Procedure – Lecture 3 Introduction Lecture 3 focuses on constitutional protections in criminal proceedings, covering the Fifth and Sixth Amendments and pretrial and trial procedures. Key Topics: Fifth Amendment: Protection against self-incrimination, Miranda warnings, and double jeopardy. Sixth Amendment: Right to counsel, a speedy trial, an impartial jury, and confrontation of witnesses. Pretrial & Trial Procedures: Grand juries, bail, plea bargaining, discovery, burden of proof, sentencing, and post-conviction relief. I. The Fifth Amendment Protects individuals from coerced confessions and multiple prosecutions. A. Miranda Rights & Custodial Interrogation Miranda v. Arizona (1966): Suspects must be informed of right to remain silent and counsel. Failure to provide warnings may make confessions inadmissible. Exceptions: Public safety, spontaneous statements, and routine booking questions. B. Voluntary Confessions & Self-Incrimination Confessions must be voluntary—coercion makes them inadmissible. Exclusionary rule bars evidence obtained in violation of Miranda. Privilege against self-incrimination applies only to testimonial evidence. C. Double Jeopardy Prohibits multiple prosecutions or punishments for the same offense. Exceptions: Separate sovereigns doctrine, mistrials, and appeals. II. The Sixth Amendment Guarantees fair trial rights. A. Right to Counsel Gideon v. Wainwright (1963): Indigent defendants must be provided counsel. Applies at all critical stages, including plea negotiations and sentencing. Strickland v. Washington (1984): Defendants may claim ineffective assistance of counsel. B. Speedy & Public Trial Barker v. Wingo factors: Length, reason, defendant's assertion, and prejudice. Speedy Trial Act (1974): Federal trials must start within 70 days. C. Impartial Jury Batson v. Kentucky (1986): Prohibits racial discrimination in jury selection. Ramos v. Louisiana (2020): Criminal convictions require unanimous verdicts. D. Confrontation Clause Right to cross-examine witnesses. Bruton v. United States (1968): Co-defendant's confession cannot be used against another defendant. Maryland v. Craig (1990): Limited exceptions for child victims. III. Pretrial & Trial Procedures Focuses on probable cause, bail, plea deals, burden of proof, and sentencing. A. Grand Juries & Bail Grand juries determine probable cause, but defendants cannot present evidence. Bail must not be excessive (8th Amendment); based on flight risk, crime severity, and public safety. B. Plea Bargains & Discovery Most cases resolve through plea deals. Brady v. Maryland (1963): Prosecution must disclose exculpatory evidence. C. Burden of Proof at Trial Prosecution must prove guilt beyond a reasonable doubt. Direct vs. Circumstantial Evidence: Direct = witnesses, videos; Circumstantial = motive, behavior. D. Sentencing & Post-Conviction Relief Mandatory minimums limit judicial discretion. Death penalty restrictions: Roper v. Simmons (2005) bars execution of juveniles. Appeals & Habeas Corpus: Review constitutional errors. Wrongful Convictions: DNA evidence & Innocence Project help exonerate the falsely accused. Conclusion Today covered constitutional protections, trial rights, and post-conviction remedies. These safeguards ensure fairness, prevent wrongful convictions, and protect due process. Tomorrow, we will examine criminal appeals and habeas corpus petitions.

"In B cell malignancies, BTKi inhibits that BTK enzyme which is very upstream. It tells NF-κB to stop signaling into the nucleus and then inhibits proliferation and survival of B cells."  Puja Patel, PharmD, BCOP, Clinical Oncology Pharmacist at Northwestern Medicine Cancer Center at Delnor Hospital in Geneva, IL, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about BTK inhibitors.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 1.0 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 17, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learners will report an increase in knowledge related to the BTK inhibitor drug class.  Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series  ONS Voice articles:  BTK Inhibitor Effective for Relapsed Hairy Cell Leukemia  FDA Grants Accelerated Approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma  Ibrutinib Is the First Anticancer Agent to Be Negotiated for Medicare Drug Pricing  Oncology Drug Reference Sheet: Pirtobrutinib  Oncology Drug Reference Sheet: Zanubrutinib  ONS books:  Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition)  Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition)  Clinical Journal of Oncology Nursing article: B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management  ONS courses:   ONS Cancer Biology™  ONS/ONCC Chemotherapy Immunotherapy Certificate™   Safe Handling Basics   ONS Guidelines™ and Symptom Interventions:   Chemotherapy-Induced Diarrhea  Prevention of Bleeding  Prevention of Infection: General  ONS Learning Library: Oral Anticancer Medication  ONS/NCODA/HOPA/ACCC's Oral Chemotherapy Education Sheets  Other resources:  Advanced Practice Providers Oncology Summit  Ash Publications article: Managing Toxicities of Bruton Tyrosine Kinase Inhibitors  Blood Advances article: BTK Inhibitors in CLL: Second-Generation Drugs and Beyond  CLL Society Fact Sheets  International Journal of Molecular Sciences article: Bruton's Tyrosine Kinase Inhibitors: Recent Updates  National Cancer Institute article: Two Drugs Show Efficacy against Common Form of Leukemia  National Comprehensive Cancer Network Guidelines for Patients: Chronic Lymphocytic Leukemia  National Study of Lymphoma (University of Oxford network site-specific group— Hematology)  NCODA's Positive Quality Intervention resources  Pharmacy Times BTK Inhibitor Comparison Charts  ScienceDirect article: Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse  The Video Journal of Hematology and Hematological Oncology  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.    Highlights From This Episode  “1952 we have the discovery by Colonel Ogden Bruton of that severe immunodeficiency due to lack of B-cell maturation, and next linked to e-gamma globular anemia. In 1993, we had Professor Vetrie and colleagues discover that this was actually due to mutation in a kinase, and they called that BTK. And then in 1993 was a discovery of our first BTKi inhibitor in the lab setting, and that's called LFM-A13. It wasn't until 2013, so that's 20 years after BTK kinase was discovered, where ibrutinib was our first-in-class BTK inhibitor, and the success of ibrutinib really promoted the exploration of second- and third-generation BTKis.” TS 6:24     “It's thought that BTK and other members in the pathway are constitutively phosphorylated, which just means they're spontaneously on. This leads to this uncontrolled activation of NF- κB signaling and thus uncontrolled proliferation and suppression of apoptosis. So, these B cells are rapidly dividing, but they're not functioning like they're supposed to be, meaning they won't differentiate, or, you know, they won't grow up to be either a plasma cell, like we talked about, or a memory B cell. They've been hacked.” TS 10:11     “This class is generally called—if you have to think of an umbrella term—it's just called targeted small molecule therapies. Now a subclass is BTKi or Bruton tyrosine kinase inhibitors. So, we're really shifting away from the use of cytotoxic chemotherapy, which is kind of designed to indiscriminately destroy rapidly dividing cells, to a more precise approach of targeting cells based on specific molecular changes in tumor DNA.” TS 13:47     “Cardiac toxicity can manifest as atrial fibrillation. And here I'll specifically talk about ibrutinib values because we have the most data with it, and the numbers actually get better with second- and third-generation BTKis. So frequency: Grade 1–2 atrial fibrillation was reported in 12%–15% of patients on Ibrutinib. And grade 3 AFib is 3%–5%. The onset, median onset is 8–13 months.” TS 20:23     “For nurses, they should really advise their patients that the caliber of headaches are easily managed and they will decrease over time over a period of four weeks. This is an upfront conversation reassuring the patient that this is not a long-term side effect.” TS 33:47     “One aspect that was being discussed at length was kind of identifying biases and then methods to neutralize those biases. So, I think first you have to identify what your bias could be toward BTK, maybe it's age or comorbidities or side-effect profile. And then, how can we mitigate our own biases is kind of the solution part to that.” TS 46:26 

Back with my first episode of 2025 talking college football playoffs with Dylan Bruton, giving you my 2025 NBA MVP ladder, and reflecting on 2024.

Unionists fiercely resist calls for a border poll for on a United Ireland, but that was not always the case. David Trimble campaigned for a poll in 2002 – secret files reveal he was dismissed. Newly released Dublin files reveal former taoiseach John Bruton was suspicious not only of Sinn Féin and the SDLP, but even his own Department of Foreign Affairs. Other files reveal a young John F Kennedy was happy enough with partition of Ireland and how Roger Casement was a source of controversy long after his execution. Ralph Reigel from the Irish Independent joins Ciarán Dunbar. Hosted on Acast. See acast.com/privacy for more information.

Today we are bringing you a conversation on treatment with Bruton tyrosine kinase inhibitors for patients with treatment-naïve chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Ryan Haumschild, PharmD, MS, MBA, CPEL, vice president of ambulatory pharmacy at Emory Healthcare and Winship Cancer Institute, spoke with 3 experts: Tara Graff, DO, medical oncologist, Mission Cancer and Blood; Jacqueline Barrientos, MD, MS, chief, Hematologic Malignancies, and director, Oncology Research at Mount Sinai Comprehensive Cancer Center; and Matthew Davids, MD, MMSc, director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School. They covered a wide range of topics including the data on treatment regimens for both CLL and MCL, the cost of treatment, patient-specific considerations during treatment decision making, and the future of treatment.

NBL NOW | Everything NBL Cal Bruton & Jack Heverin The great Cal Bruton talks World Basketball Day with Jack HeverinSee omnystudio.com/listener for privacy information.

This is the last episode of series 3. I have absolutely loved chatting to all the guests and feel very grateful for having met such inspiring people. Today's conversation is with Rosanna Philpott, founder of Pygmalion, a dinner candle company launched in August of this year. Lighting a tall dinner candle in anticipation for the arrival of guests, really is the moment before the fun is about to commence. Rosanna has developed candles that capture this magic with designs that are modern, fun and look great placed on any table or mantle.Rosanna and I chat through the story behind the name Pygmalion and how her painting and travels to Kenya have inspired the candle designs. I hear about how hard it was finding her factory and the disasters she's had along the way. Rosanna really is finessing the art of multitasking. Not only does she run Pygmalion but she has a full time job as a features reporter for a large news network. Incredible. I am delighted to say that Pygmalion candles are part of the pop-up I'm doing in Bruton at the moment and they are flying off the shelves. They are the perfect gift this Christmas. Please welcome to the podcast, the very dynamic Rosanna Philpott. Hosted on Acast. See acast.com/privacy for more information.

Among the latest data being presented at the American Society of Hematology Annual Meeting and Exposition, held December 7-10, 2024, in San Diego, California, were 3 abstracts that focused on patient preferences and treatment choices. Sikander Ailawadhi, MD, professor of medicine in the Division of Hematology/Oncology at the Mayo Clinic Florida was a coauthor on all 3 abstracts, covering patient preferences for Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma, survivorship burden and patient preferences affecting treatment choices in multiple myeloma, and race/ethnicity-specific sociodemographic and economic factors driving refusal of treatment in multiple myeloma.

Freight HHG has been on my radar for many years. With a paired back and tactile aesthetic, the acclaimed shop based in Lewes, Sussex understands the importance of materiality, beauty and the importance of creating atmospheric spaces. Launched in 2014, mother Helene, and daughter Adele, seem to have formed quite the duo with a wonderful mix of discernment, technical ability and the art of editing. Freight HHG - standing for Household Goods - have been a benchmark for me with Caro, as my team will have testified, so it was an absolutely privilege to chat with Adele - especially as she only gave birth 5 weeks ago to her son Kit. With a business model based in uk production, I was curious to hear how they have got on amongst the turbulent few years we've had - but also about the journey they've had growing a business that has confidence and an abundance of charm.Adele has such an eloquent way of talking shop. I am thrilled to say, I am selling their beautiful wares in my Pop Up - which is on now at The Space in Bruton until the 21st December - as well as on carosomerset.comPlease welcome Adele Adamczewski. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bruton Agammaglobulinemia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Immunology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Zara Peters is the lovely face behind the name Queen of Bows. I don't know if you've noticed, but bows are featuring in quite a gib way at the moment and I am certain that it is something to do with Zara's bows because her's aren't just any bows. From giant, oversized bows to bows to put on cars, mantelpieces and front doors, Zara hand makes to order in a beautiful range of understated, natural fabrics. I am overjoyed to say that her bows, as well as her scrunchies will be at my pop-up starting this Saturday - at The Space in Bruton, please see my instagram profile for more details - Zara's bows just have this way of making everything feel festive and special.We have such a lovely conversation with rather a funny moment in the middle when we clear up a confusion we had around her thinking I called her a giant Elf - thank god we cleared that one up. As it's Christmas, I ask a few festive inspired questions which had a heartwarming turn this episode - I have been inspired talking to Zara about her take on Christmas and the traditions she invites her family to take part in.Lot's jingly bells to all of you and enjoy this festive episode. Hosted on Acast. See acast.com/privacy for more information.

The next few guests on the podcast are the founders of brands that I have invited to be a part of the Caro Pop-Up running for 2 weeks, starting on the 7th December in The Space in Bruton.Katie Leamon, was the first stationery brand I bought for Caro. Introduced to me by a mutual friend, I remember the eponymous marble collection selling out extremely fast. You can now find her greetings cards, wrap and notebooks in a number of luxury stores across the world including Harrods, Fortnum & Mason & Selfridges as well as many independent shops.We meet online and talk about the beginnings of her business - catapulted in 2010, after Liberty picked her up at one of their Open call days. We chat about how she's grown her brand and seen various iterations of what that looks like as well as where Katie Leamon is heading. We chat about the memorabilia that inspires her and how her designs organically evolve with her aesthetic but also her customers. I am excited to introduce her ReLove Christmas Collection to the pop-up, with traditionally illustrated fathers Christmas', reindeer and snow-topped cottages - it truly brings that nostalgic feeling we all love at this time of year. Hosted on Acast. See acast.com/privacy for more information.

Built airplane. Flew airplane. Crashed airplane. Met God. all set.Jim Bruton knows life. His past is marked by relentless curiosity and remarkable achievement. He was an African wilderness guide, Emmy Award-winning wildlife film director, aviator, adventurer, inventor of the satellite videophone, NBC News Middle East war correspondent, a husband, and a father.His passion - building and flying WWI-era aircraft - led him where he never imagined he'd go: a horrific crash that left him for dead. For one week, Jim Bruton hovered in the place that is not life and not death, a place he came to know as the In Between. He came back, and this is his report of what he has seen.Bruton takes us along for a by turns hair-raising and ultimately triumphant story of his coming to grips with what has happened to him. As he heals, his experiences in the In Between become more and more pressing. They download into his mind like rushing movie stills. His life of action turns internal. He uses all he knows - from quantum physics and battlefield memories to scenes of childhood and familial love - for a new deeper understanding of what it means to live.Jim Bruton, the man who fell from the sky, is not the same man who flew into it. And if you walk some of his journey with him, neither are you.About the author: Jim Bruton has lived a life many people dream of but few experience. As a little boy, he lived within an active imagination, including a love for wildlife filming, international travel, science fiction, and vintage aviation. In adulthood, he checked every one of those off his list with internationally recognized achievements, an Emmy for a National Geographic wildlife film, traveling to all seven continents, the Titanic, the North Pole, and Mt. Everest, shrinking a satellite TV truck into a backpack, and transmitting live video from places before impossible and building and flying historical reproduction aircraft from World War I and the early 1930s.For many, any one of these adventures resulted in a single lifetime achievement. For Jim, it was just the beginning, climaxing with the crash of his last aircraft and the near-death experience that followed.Jim is an Emmy award winning journalist and in this episode we talk about his about his Near Death Experience.From Jim's website;Generally, people who have had NDEs aren't trying to “sell” anything, other than perhaps a seminar, book or DVD.  We don't try to sell a new religion, because we left all that behind.  However, spirituality plays a pretty strong role in the experiences we share.  One of the strangest things I've noticed is that for those of us who had our NDEs as a result of some horrific accident, while in most cases the accident and its crazy circumstances would be the focus of any compelling story, an NDE negates that.Once an NDE enters the picture, you almost forget about the accident- it becomes the least important part of the story, next to the NDE.  My accident was amazing as accidents go, and I have an NDE friend who is only one of a handful in the world that she knows of who suffered and survived an internal decapitation.  But to NDE'ers, the circumstances that nearly, or do, kill us are just a footnote.  I'm sure that must be surprising, in some way.https://www.inbetweenproductions.com/https://www.amzn.com/dp/B098KQHX57 https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlife

Join host Dan Dworkis on The Emergency Mind Podcast as he interviews Vinton Bruton, Director of the Wilson Center for Leadership in the Public Interest at Hampden-Sydney College. Drawing on his diverse background as a Marine infantry officer, educator, and volunteer firefighter, Vinton shares insights on leadership development, character education, and the importance of experiential learning. Discover how principles from the military and outdoor adventure can be applied to teaching the next generation of leaders in various high-pressure environments, including emergency medicine. Don't miss this engaging discussion on developing effective, resilient leaders for tomorrow's challenges.

Built airplane. Flew airplane. Crashed airplane. Met God. all set.Jim Bruton knows life. His past is marked by relentless curiosity and remarkable achievement. He was an African wilderness guide, Emmy Award-winning wildlife film director, aviator, adventurer, inventor of the satellite videophone, NBC News Middle East war correspondent, a husband, and a father.His passion - building and flying WWI-era aircraft - led him where he never imagined he'd go: a horrific crash that left him for dead. For one week, Jim Bruton hovered in the place that is not life and not death, a place he came to know as the In Between. He came back, and this is his report of what he has seen.Bruton takes us along for a by turns hair-raising and ultimately triumphant story of his coming to grips with what has happened to him. As he heals, his experiences in the In Between become more and more pressing. They download into his mind like rushing movie stills. His life of action turns internal. He uses all he knows - from quantum physics and battlefield memories to scenes of childhood and familial love - for a new deeper understanding of what it means to live.Jim Bruton, the man who fell from the sky, is not the same man who flew into it. And if you walk some of his journey with him, neither are you.About the author: Jim Bruton has lived a life many people dream of but few experience. As a little boy, he lived within an active imagination, including a love for wildlife filming, international travel, science fiction, and vintage aviation. In adulthood, he checked every one of those off his list with internationally recognized achievements, an Emmy for a National Geographic wildlife film, traveling to all seven continents, the Titanic, the North Pole, and Mt. Everest, shrinking a satellite TV truck into a backpack, and transmitting live video from places before impossible and building and flying historical reproduction aircraft from World War I and the early 1930s.For many, any one of these adventures resulted in a single lifetime achievement. For Jim, it was just the beginning, climaxing with the crash of his last aircraft and the near-death experience that followed.Jim is an Emmy award winning journalist and in this episode we talk about his about his Near Death Experience.From Jim's website;Generally, people who have had NDEs aren't trying to “sell” anything, other than perhaps a seminar, book or DVD.  We don't try to sell a new religion, because we left all that behind.  However, spirituality plays a pretty strong role in the experiences we share.  One of the strangest things I've noticed is that for those of us who had our NDEs as a result of some horrific accident, while in most cases the accident and its crazy circumstances would be the focus of any compelling story, an NDE negates that.Once an NDE enters the picture, you almost forget about the accident- it becomes the least important part of the story, next to the NDE.  My accident was amazing as accidents go, and I have an NDE friend who is only one of a handful in the world that she knows of who suffered and survived an internal decapitation.  But to NDE'ers, the circumstances that nearly, or do, kill us are just a footnote.  I'm sure that must be surprising, in some way.https://www.inbetweenproductions.com/https://www.amzn.com/dp/B098KQHX57/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlife

In this episode of VisionCraft Presents Coffee in the Green Room, host Deneen White has a deeply moving conversation with Lori Bruton, a woman who overcame profound personal struggles and emerged stronger and more determined than ever to help others break free from toxic relationships. Lori shares her personal journey, beginning with a seemingly perfect life that took unexpected turns, leading her through hardship, a painful toxic relationship, and ultimately a transformation that inspired her to empower others.Lori's story is one of hope and resilience. After experiencing a major life breakdown, she found herself in a relationship that drained her sense of self. It was only through the support of friends, mentors, and her own determination that she was able to reclaim her life. Lori also dives into her work as a writer, discussing her first book, Whole to Whole: Journey to Hope and Transformation, a testament to her journey toward self-discovery and healing. With honesty, she shares her defining moments, from a pivotal experience on stage with renowned transformation coach Gary Coxe, to her courageous steps toward building a new life.Tune in to this inspiring conversation as Lori discusses how she went from merely surviving to thriving. Whether you're overcoming your own challenges or simply need a dose of hope, Lori's words are sure to resonate. Follow Lori's journey and find out more about her work by visiting LoriBruton.com.VISION CRAFT COUSEhttps://www.visioncraftcourse.com/REGISTER FOR OUR NEXT ONLINE, NO-COST AUDITIONhttps://www.ammsociety.com/CHECK OUT VIP IGNITE'S FREE MODEL AND ACTOR BOOTCAMPhttps://vipignitesummit.comFOR MORE INFORMATION ABOUT VIP IGNITE https://vipignitelive.com/CHECK US OUT ON FACEBOOK:https://www.facebook.com/vipigniteliveCHECK US OUT ON INSTAGRAMhttps://www.instagram.com/vipigniteCHECK US OUT ON TWITTER:https://www.twitter.com/vipigniteCHECK OUT THE HOLLYWOOD MINDSET WEBSITE HERE:https://www.hollywoodmindset.comCHECK OUT THE COFFEE IN THE GREEN ROOM PODCAST HERE:https://www.coffeeinthegreenroom.comCHECK OUT THE VIP IGNITE LIVE PODCAST HERE: https://www.vipignitelivepodcast.comCHECK OUT WHAT PEOPLE ARE SAYING HERE:https://www.youtube.com/playlist?list=PLLzqEyOG...

In this episode, we meet Jim Bruton, a man who has traveled the world, chased storms, reported from war zones, and worked in realms many would only dream of. But in a twist of fate, a plane crash brought him somewhere altogether unexpected—the in-between. From this surreal vantage point, Jim experienced a near-death journey that went beyond the usual light and tunnel, plunging him into a vast landscape of choices, probabilities, and life's potential futures.Jim's adventure starts with a daring passion for aviation. In 2016, while testing his homemade plane, his engine cut out mid-air, sending him into a violent crash. That moment of impact shattered not only his body but his concept of reality. In the haze of unconsciousness, Jim describes suddenly “teleporting” to what felt like a post-apocalyptic cityscape, where a sense of calm enveloped him. There was no fear, just the quiet understanding that he was somewhere beyond the ordinary—standing in what he would come to call “the eternity of a single moment.”As Jim looked around, he noticed a towering, latticed egg filled with gears, each one delicately hovering in space. The gears represented choices, futures, and possibilities, he explained, and each one could be felt rather than seen. Some gears brought a sense of peace; others, when touched, emitted a wave of nausea or pain, signaling a choice that could lead to suffering. “It's the process of becoming,” a disembodied voice told him, urging Jim to engage with his own fate as he would a living puzzle.In this vast in-between, Jim began removing the “painful” gears, choices that would have led him to spiritual dead-ends. One gear hinted at a lottery win, yet the pull of its danger told Jim that path would derail his journey, leading him away from his spiritual progress. His reflex was to let it go, casting the gear aside as it dissolved into the space around him. "For those who make poor use of their choices, offering fewer possibilities could be called Mercy," the voice added, an insight that profoundly shifted Jim's understanding of free will and destiny.This experience wasn't passive; Jim was in control, an active participant in navigating the paths his life could take. His choices in that space weren't just about personal gain—they were about finding the right road to spiritual evolution, learning to let go of what no longer served him. The voice urged him to remember that each decision has unseen impacts, rippling through time and space, shaping not only his life but all connected to him.After what seemed like an eternity, Jim was directed back to the waking world with a final message: “Pay attention to your relationships.” This wisdom stayed with him, offering a new perspective on the bonds that shape us. Since his experience, Jim finds that people are drawn to him in a different way, responding to a quiet, unspoken depth within him. His near-death journey left him with a gentle detachment, one that allows him to see beyond the surface and connect more authentically with others.Jim's return to life wasn't just about survival; it was about living with intentional awareness, treating each interaction as an opportunity for growth and understanding. His journey through the in-between was a reminder that we are not here to amass things or fulfill ambitions but to evolve spiritually, to learn, and, ultimately, to let go.SPIRITUAL TAKEAWAYSEmbrace Your Choices with Reverence: Jim's journey reminds us that each choice shapes not just our future but our spiritual trajectory. Trusting the "grand design" helps us make decisions aligned with a higher path.Life as a Mosaic of Connections: Every relationship, Jim shares, carries an unseen purpose. By nurturing these connections and living authentically, we align closer to our spiritual essence.Detach and Let Go: The true power, Jim says, lies in the art of letting go. When we release attachment, we allow life to unfold organically, connecting us to our higher purpose.Please enjoy my conversation with Jim Bruton.Become a supporter of this podcast: https://www.spreaker.com/podcast/next-level-soul-podcast-with-alex-ferrari--4858435/support.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/BTKInhibitorsMCL24).

Send us a textLisa Bruton is a speaker, podcaster, and founder and director of Arise Sanctuary, an organisation that has offered over 45 luxury boutique retreats for women in locations around the world. She is passionate about creating spaces for others to slow down, connect to God and hear His voice.Lisa has spoken at conferences and churches throughout Australia and overseas, where she openly shares her heart, funny mishaps, lessons and revelations. Lisa is a wife to Matty and mum to two young girls, Aria and Coco. In her spare time, she loves to surf and travel with herfamily.Support the showwww.greaterthingsinternational.com

In this episode of The Run the Riot Podcast, David chats with Alex Bruton, a newly dedicated ultrarunner and participant in the Run the Riot coaching program. Fresh off achieving a monumental goal—running 50 kilometers for his 50th birthday—Alex shares the incredible journey of preparing for his big challenge. Throughout the conversation, Alex and David discuss how ultrarunning, like Alex's personal "moonshot" projects, pushes the boundaries of mental and physical endurance. Tune in to hear Alex's reflections on the importance of believing in yourself, embracing the grit, and finding the joy in every milestone. Alex also dives into how this ultrarunning journey parallels his work in innovation, especially with his Moonshot Opportunity System (Moonshot OS), helping individuals achieve massive goals. They also touch on his heartfelt cause: raising funds for Give a Mile, a charity that provides flights for families to reunite during times of terminal illness. Show notes here: http://www.theriot.run/alexb If you're ready to push your limits and take on new challenges, check out our coaching page at Run the Riot Coaching. Hashtags: #runtheriot #ultrarunning #ultrarunner #trailrunning #moonshot #trailrunner #50kmrun

The coelacanth was believed to have gone extinct about 66 million years ago, until one was spotted in South Africa in 1938. Naturalist and museum curator Marjorie Courtenay-Latimer played a key part in that event. Research: Ashworth, Willam B. Jr. “Scientist of the Day – Marjorie Courtenay-Latimer.” Linda Hall Library. 2/24/2020. https://www.lindahall.org/about/news/scientist-of-the-day/marjorie-courtenay-latimer/ Bruton, Mike. “Curator and Crusader: The Life and Work of Marjorie Courtenay-Latimer.” Pinetown Printers, 2019. Courtenay-Latimer, M. “My Story of the First Coelacanth.” Occasional Papers of the California Academy of Sciences. No. 134. 12/22/1979. https://www.biodiversitylibrary.org/page/15956893#page/18/mode/1up Courtenay-Latimer, Marjorie. “Reminiscences of the Discovery of the Coelacanth, Latimeria chalumnae.” Interdisciplinary Journal of the International Society of Cryptozoology. Vol. 8. 1989. Hatchuel, Martin. “The Coelacanth.” Knysna Museums. https://www.knysnamuseums.co.za/pages/the-coelacanth/ Jewett, Susan L. “Marjorie Courtenay-Latimer: More than the Coelacanth!” Division of Fishes, Smithsonian Institution. Schramm, Sally. “Marjorie Eileen Doris Courtenay-Latimer: Beyond the Coelacanth.” Biodiversity Heritage Library Blog. https://blog.biodiversitylibrary.org/2019/03/marjorie-eileen-doris-courtenay-latimer.html Smith, Anthony. “Marjorie Courtenay-Latimer.” The Guardian. 5/20/2004. https://www.theguardian.com/news/2004/may/21/guardianobituaries Smith, J.L.B. “The Living Cœlacanthid Fish from South Africa.” Nature 143, 748–750 (1939). https://doi.org/10.1038/143748a0 Smith, J.L.B. “The Search Beneath the Sea: The Story of the Coelacanth.” New York. Holt. 1956. Smith, J.L.B. Living Fish of Mesozoic Type.” Nature 143, 455–456 (1939). https://doi.org/10.1038/143455a0 The Coelacanth : the Journal of the Border Historical Society. Vol. 42 No. 1 (2004). https://journal.ru.ac.za/index.php/Coelacanth/issue/view/143 Tyson, Peter. “Moment of Discovery.” PBS Nova. https://www.pbs.org/wgbh/nova/fish/letters.html Weinberg, Samantha. “A Fish Caught in Time: the Search for the Coelacanth.” New York : HarperCollins Publishers. 2001. Yanes, Javier. “The Woman Who Brought a Fish Back From the Dead.” BBVA Open Mind. 2/17/2023. https://www.bbvaopenmind.com/en/science/leading-figures/marjorie-courtenay-latimer-fossil-fish-coelacanth/ See omnystudio.com/listener for privacy information.

American author Robert Bruton takes us through his Master's thesis on the role of climate change and plague in the decline of Roman fortunes in the 6th century.He is also writing a trilogy of historical fiction novels about the life of Belisarius. Find out more about Robert and his work here. Hosted on Acast. See acast.com/privacy for more information.